

DAFTAR PUSTAKA

1. Tan PY, Anand SP, Chan DXH. Post-mastectomy pain syndrome: a timely review of its predisposing factors and current approaches to treatment. *Proc Sing Health*. 2022;31:1–5.
2. Narisuari IDAPM, Manuaba IBTW. Prevalensi dan gambaran karakteristik penderita kanker payudara di poliklinik bedah onkologi RSUP Sanglah, Bali, Indonesia tahun 2016. *Intisari Sains Medis*. 2020;11(1):183–9.
3. Suhaid DN, Wardani DWKK, Aningsih BSD, Manungkalit EM, Kusmiyanti M. Deteksi dini kanker serviks dan payudara dengan pemeriksaan IVA serta SADANIS di perumahan kartika sejahtera kelurahan sasak panjang kecamatan tajur halang kabupaten bogor jawa barat. *J Kreat Pen Masyarakat*. 2022;5(2):406–13.
4. Al –Gaithy ZK, Yaghmoor BE, Koumu MI, Alshehri KA, Saqah AA, Alshehri HZ. Trends of mastectomy and breast-conserving surgery and related factors in female breast cancer patients treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009–2017: a retrospective cohort study. *AMAS*. 2019;41:47–52.
5. Ng LXL, Ng MHX, Mok CW, Lee WP, Tan SM, Woon KL. A comparison of local infiltration analgesia and PECS II block for analgesia in mastectomy with axillary dissection: a randomised equivalence study. *Open J Anesthesiol*. 2021;11(08):229–42.
6. Mahajan S, Kaushal S. Comparison of local infiltration with modified pectoralis block for post-operative analgesia after modified radical mastectomy: an open label randomized trial. *Indian J Anesth*. 2019;6(5):1635–40.
7. Canikli AŞ, Akyurt D, Bahadır AH, Tulgar S, Ültan OG. Can neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, or systemic immune inflammation

index be an indicator of postoperative pain in patients undergoing laparoscopic cholecystectomy?. *Cureus*. 2023;15(1):1–10.

8. Sercan O, Karaveli A, Ozmen S, Uslu A. Comparison of the effects of pectoral nerve block and local infiltration anesthesia on postoperative pain for breast reduction surgery: a prospective observational study. *Eurasian J Med*. 2021;53(2):102–7.
9. Jacobs A, Lemoine A, Joshi GP, Van de Velde M, Bonnet F, Pogatzki-Zahn E, et al. PROSPECT guideline for oncological breast surgery: a systematic review and procedure-specific postoperative pain management recommendations. *Anaesthesia*. 2020;75(5):664–73.
10. Syal K, Chandel A. Comparison of the post-operative analgesic effect of paravertebral block, pectoral nerve block and local infiltration in patients undergoing modified radical mastectomy: a randomised double-blind trial. *Indian J Anaesth*. 2017;61(8):643–8.
11. Cheng GS, Ilfeld BM. An evidence-based review of the efficacy of perioperative analgesic techniques for breast cancer-related surgery. *Pain Med*. 2017;18(7):1344–65.
12. Indra B, Lipoeto NI, Tjong DH, Rahman S. Alteration of interleukin-4, interleukin-6 levels, and post-operative pain intensity. *Open Access Maced J Med Sci*. 2023;11(1):1–7.
13. Haddadi K, Abediankenari S, Alipour A, Ghazvini HRG, Jafarpour H, Asadian L, et al. Association between serum levels of interleukin-6 on pain and disability in lumbar disc herniation surgery. *Asian J Neurosurg*. 2020;15(3):494–501.
14. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. *Int J Mol Sci*. 2022;23(7):1–5.

15. Malik NA. Revised definition of pain by “international association for the study of pain”: concepts, challenges and compromises. *Anaesth, Pain and Inten Care*. 2020;24(5):481–3.
16. Yam MF, Loh YC, Tan CS, Adam SK, Manan NA, Basir R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. *Int J Mol Sci*. 2018;19(8):1–7.
17. Rivasi G, Menale S, Turrin G, Coscarelli A, Giordano A, Ungar A. The effects of pain and analgesic medications on blood pressure. *Curr Hypertens Rep*. 2022;24(10):385–94.
18. Reddi D, Curran N. Chronic pain after surgery: pathophysiology, risk factors and prevention. *Postgrad Med J*. 2014;90(1062):222–7.
19. Eisenach JC, Brennan TJ. Pain after surgery. *Pain*. 2018;159(6):1010–1.
20. Bonezzi C, Fornasari D, Cricelli C, Magni A, Ventriglia G. Not all pain is created equal: basic definitions and diagnostic work-up. *Pain Ther*. 2020;9(1):1–10.
21. Dubin A, Patapoutian A. Nociceptors: the sensors of the pain pathway. *J Clin Investigation*. 2010;120(1):3760–72.
22. Cook AD, Christensen AD, Tewari D, McMahon SB, Hamilton JA. Immune cytokines and their receptors in inflammatory pain. *Trends Immunol*. 2018;39(3):240–55.
23. Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, et al. Validation of digital visual analogue scale pain scoring with a traditional paper-based visual analog scale in adults. *JAAOS*. 2018;2(3):82–8.
24. Manion J, Waller MA, Clark T, Massingham JN, Neely GG. Developing modern pain therapies. *Front Neurosci*. 2019;13:1–5.
25. Temple-Oberle C, Shea-Budgell MA, Tan M, Semple JL, Schrag C, Barreto M, et al. Consensus review of optimal perioperative care in breast reconstruction:

- enhanced recovery after surgery (ERAS) society recommendations. *Plast Reconstr Surg*. 2017;139(5):1056e–71e.
26. Battista C, Krishnan S. Pectoralis nerve block. *StatPearls*. 2019;1–5.
 27. Safari S, Rahimzadeh P, Haghighi M. Local infiltration anesthesia: does it really work?. *Ann Transl Med*. 2015;3(18):275–83.
 28. Joshi GP, Janis JE, Haas EM, Ramshaw BJ, Nihira MA, Dunkin BJ. Surgical site infiltration for abdominal surgery: a novel neuroanatomical-based approach. *Plast Reconstr Surg Glob Open*. 2016;4(12):1–7.
 29. Stamenkovic DM, Bezmarevic M, Bojic S, Unic-stojanovic D, Stojkovic D, Slavkovic DZ, et al. Updates on wound infiltration use for postoperative pain management: a narrative review. *J Clin Med*. 2021;10(20):1–12.
 30. Kesici S, Kesici U, Ulusoy H, Erturkuner P, Turkmen A, Arda O. Effects of local anesthetics on wound healing. *Brazilian J Anesth*. 2018;68(4):375–82.
 31. Latham JL, Martin SN. Infiltrative anesthesia in office practice. *Am Fam Physician*. 2014;89(12):956–62.
 32. Abrão J, Antunes M, Vicente Garcia L. Local anesthetics infiltration and wound healing process. *Topics Local Anesth*. 2019;1–16.
 33. Sebba A. Pain: a review of interleukin-6 and its roles in the pain of rheumatoid arthritis. *Open Access Rheumatol*. 2021;13:31–43.
 34. Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. *J Scleroderma Relat Disord*. 2017;2:S1–5.
 35. Qu D, Liu J, Lau CW, Huang Y. IL-6 in diabetes and cardiovascular complications. *Br J Pharmacol*. 2014;171(15):3595–603.
 36. Hirano T. IL-6 in inflammation, autoimmunity and cancer. *Int Immunol*. 2021;33(3):127–48.

37. Caiello I, Minnone G, Holzinger D, Vogl T, Prencipe G, Manzo A, et al. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. *PLoS One*. 2014;9(10).
38. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. *Nat Rev Rheumatol*. 2017;13(7):399–409.
39. Gabay C. Interleukin-6 and chronic inflammation. *Arthritis Res Ther*. 2006;8(2):1–6.
40. Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M, Shahveranov A, et al. Interleukin-6: an emerging regulator of pathological pain. *J Neuroinflammation*. 2016;13(1):1–5.
41. Doran C, Yi X. The anti-inflammatory effect of local anesthetics. *Pain Clin*. 2007;19(5):207–13.
42. Iinuma K, Enomoto T, Kawada K, Fujimoto S, Ishida T, Takagi K, et al. Utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab and ipilimumab. *J Clin Med*. 2021;10(22):10–7.
43. Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically ill and injured patients: which ratio to choose to predict outcome and nature of bacteremia?. *Med Inflam*. 2018;2018:15–27.
44. Kourilovitch M, Galarza-Maldonado C. Could a simple biomarker as neutrophil-to-lymphocyte ratio reflect complex processes orchestrated by neutrophils?. *J Transl Autoimmun*. 2023;6:159–65.

45. Alkan M, Erkent FD, Celik A, Gokce A, Arslan M, Unal Y. Effects of thoracic epidural or intravenous analgesia on the neutrophil-to-lymphocyte ratio in thoracotomy cases. *Niger J Clin Pract.* 2018;21(10):1337–40.
46. Desiree P, Surya Airlangga P, Kriswidyatomo P, Soemartono Waloejo C, Santosa DA, Pujo Semedi B, et al. Effect of scalp block with 0.5% ropivacaine on interleukin-6 and neutrophil lymphocyte ratio in elective craniotomy. *Bali Med J.* 2024;13(1):668–74.
47. Bagry H, de la Cuadra Fontaine JC, Asenjo JF, Bracco D, Carli F. Effect of a continuous peripheral nerve block on the inflammatory response in knee arthroplasty. *Reg Anesth Pain Med.* 2008;33(1):17–23.
48. Lu IC, Huang SH, Vi Lu D, Dan Hsu C, Hua Wu S. Combination preemptive peripheral nerve block in limb surgery: a prospective study. *Medicina (Lithuania).* 2020;56(8):1–11.
49. Weinschenk S, Weiss C, Benrath J, von Baehr V, Strowitzki T, Feißt M. Anti-inflammatory characteristics of local anesthetics: inhibition of TNF- α secretion of lipopolysaccharide-stimulated leucocytes in human blood samples. *Int J Mol Sci.* 2022;23(6):1-16.
50. Kim JE, Kim KJ, Ahn W, Han KS, Kim HK. Local anesthetics inhibit tissue factor expression in activated monocytes via inhibition of tissue factor mRNA synthesis. *Clin App Thrombosis/Hemostasis.* 2011;17(6):1-6.
51. Hakim KYK, Wahba WZ. Single injection pectoral nerve block (pecs I and pecs II) versus local anesthetic infiltration for ambulatory breast augmentation combined with monitored anesthesia care. *Ain-Shams J Anesth.* 2019;11(1):1–6.
52. Argun G, Kaya I, Ünver S. Comparison of infiltration analgesia and pectoral nerve block in the pain management after mastectomy for breast cancer. *Acta Oncol Turc.* 2019;52(2):308–12.
53. Al Ja'bari A, Robertson M, El-Boghdadly K, Albrecht E. A randomised controlled trial of the pectoral nerves-2 (PECS-2) block for radical mastectomy. *Anaesthesia.* 2019;74(10):1277–81.

Lampiran 1. Surat Etik Penelitian dan Izin Penelitian.

		KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK. Telp. 081241850858, 0411 5780103, Fax : 0411-581431			
REKOMENDASI PERSETUJUAN ETIK Nomor : 173/UN4.6.4.5.31/ PP36/ 2024					
Tanggal: 15 Maret 2024					
Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :					
No Protokol	UH24020118		No Sponsor		
Peneliti Utama	dr. Jokevin Prasetyadhi		Sponsor		
Judul Peneliti	PERBANDINGAN ANTARA BLOK SARAF PEKTORALIS II DENGAN ANESTESI LOKAL INFILTRASI BUPIVAKAIN ISOBARIK 0.25% 50 MG TERHADAP RASIO NEUTROFIL-LIMFOSIT, KADAR INTERLEUKIN-6, INTENSITAS NYERI, DAN KEBUTUHAN OPIOID PASCABEDAH PADA PASIEN MASTEKTOMI RADIKAL MODIFIKA				
No Versi Protokol	2	Tanggal Versi	13 Maret 2024		
No Versi PSP	2	Tanggal Versi	13 Maret 2024		
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar				
Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal 6 Maret 2024		Masa Berlaku	15 Maret 2024 sampai 15 Maret 2025 Frekuensi review lanjutan	
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)		Tanda tangan 		
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)		Tanda tangan 		
Kewajiban Peneliti Utama: - Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan - Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan - Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah - Menyerahkan laporan akhir setelah Penelitian berakhir - Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation) - Mematuhi semua peraturan yang ditentukan					

Lampiran 2. Data Hasil Pemeriksaan Laboratorium Kadar IL-6 dengan metode ELISA.

Test items: IL-6 BT Lab

Plate No.: 167

Main wavelength: 450

cut-off:

Sub wavelength:

Tester: 1000

Testing time: 2024-04-22 11:47:23

Report time: 22/04/2024 11:48:41

Review:

	1	2	3	4	5	6	7	8	9	10	11	12
Type	STD1	3	11	19	27	35	43	51	59	67	75	83
Result	320,0000	53,1368	45,6827	47,3024	35,4633	30,3993	224,0381	75,8639	72,3725	67,3177	86,9592	96,2704
OD value	2,0757	0,5356	0,4645	0,4797	0,3731	0,3316	1,7927	0,7609	0,7262	0,6758	0,8697	0,9583
Conc	320,0000	53,1368	45,6827	47,3024	35,4633	30,3993	224,0381	75,8639	72,3725	67,3177	86,9592	96,2704
Type	STD2	4	12	20	28	36	44	52	60	68	76	84
Result	160,0000	39,9112	41,4386	40,5717	39,6414	38,2811	267,6342	52,7246	54,7794	40,5605	57,7952	75,9244
OD value	1,4667	0,4118	0,4255	0,4177	0,4094	0,3974	1,9461	0,5316	0,5516	0,4176	0,5812	0,7615
Conc	160,0000	39,9112	41,4386	40,5717	39,6414	38,2811	267,6342	52,7246	54,7794	40,5605	57,7952	75,9244
Type	STD3	5	13	21	29	37	45	53	61	69	77	85
Result	80,0000	31,8528	41,6930	89,9316	49,0007	24,9112	210,1285	62,8421	51,4835	68,4805	47,6413	102,1834
OD value	0,7880	0,3432	0,4278	0,8983	0,4958	0,2904	1,7331	0,6312	0,5196	0,6874	0,4829	1,0129
Conc	80,0000	31,8528	41,6930	89,9316	49,0007	24,9112	210,1285	62,8421	51,4835	68,4805	47,6413	102,1834
Type	STD4	6	14	22	30	38	46	54	62	70	78	86
Result	40,0000	42,8582	43,8281	100,5001	79,3427	39,4047	199,0832	66,0143	128,2989	77,8636	126,0128	127,4410
OD value	0,4299	0,4384	0,4473	0,9975	0,7953	0,4073	1,6814	0,6628	1,2355	0,7807	1,2173	1,2287
Conc	40,0000	42,8582	43,8281	100,5001	79,3427	39,4047	199,0832	66,0143	128,2989	77,8636	126,0128	127,4410
Type	STD5	7	15	23	31	39	47	55	63	71	79	87
Result	20,0000	42,3869	61,1009	102,7987	41,5382	47,9478	38,9976	50,6836	66,8065	35,0495	50,3398	94,2784
OD value	0,2542	0,4341	0,6139	1,0185	0,4264	0,4858	0,4037	0,5119	0,6707	0,3696	0,5086	0,9396
Conc	20,0000	42,3869	61,1009	102,7987	41,5382	47,9478	38,9976	50,6836	66,8065	35,0495	50,3398	94,2784
Type	BLK	8	16	24	32	40	48	56	64	72	80	88
Result	0,0000	38,3382	45,3932	57,9068	87,1558	43,9366	41,6046	48,0851	29,0012	43,7521	144,9419	103,4379
OD value	0,0000	0,3979	0,4618	0,5823	0,8716	0,4483	0,4270	0,4871	0,3207	0,4466	1,3604	1,0243
Conc	0,0000	38,3382	45,3932	57,9068	87,1558	43,9366	41,6046	48,0851	29,0012	43,7521	144,9419	103,4379
Type	1	9	17	25	33	41	49	57	65	73	81	89
Result	58,4440	50,2564	46,5479	88,2652	51,3383	193,3267	113,6110	54,6566	57,7140	68,5507	46,2601	89,6184
OD value	0,5876	0,5078	0,4726	0,8823	0,5182	1,6528	1,1142	0,5504	0,5804	0,6881	0,4699	0,8953
Conc	58,4440	50,2564	46,5479	88,2652	51,3383	193,3267	113,6110	54,6566	57,7140	68,5507	46,2601	89,6184
Type	2	10	18	26	34	42	50	58	66	74	82	90
Result	52,1876	48,6119	69,4529	91,1037	41,5825	166,8532	45,1246	77,5501	24,0003	68,4103	28,8712	106,3383
OD value	0,5264	0,4921	0,6971	0,9095	0,4268	1,5051	0,4593	0,7776	0,2840	0,6867	0,3197	1,0504
Conc	52,1876	48,6119	69,4529	91,1037	41,5825	166,8532	45,1246	77,5501	24,0003	68,4103	28,8712	106,3383

CURRICULUM VITAE

1. DATA PRIBADI

Nama Lengkap : Jokevin Prasetyadhi
 Tempat tanggal lahir : Medan, 1 Oktober 1994
 Jenis Kelamin : Laki-laki
 Kewarganegaraan : Warga Negara Indonesia
 Agama : Kristen
 Alamat : Jl. Cendrawasih IV no. 17, Makassar
 Email : jokevin.prasetyadhi@yahoo.com

2. RIWAYAT PENDIDIKAN

No	Jenjang Pendidikan	Institusi	Tahun	Tempat
1	SD	SD Kalam Kudus	2000-2006	Batam
2	SMP	SMP Global Indo Asia	2006-2009	Batam
3	SMA	SMA Djuwita	2009-2012	Batam
4	S1 & PROFESI	Fakultas Kedokteran Universitas Pelita Harapan	2012-2018	Tangerang
5	PPDS	Departemen Ilmu Anestesi, Terapi Intensif dan Manajemen Nyeri FK Universitas	2020-2024	Makassar